Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/23524
標題: 急性缺血性中風與周邊動脈阻塞疾病相關因素之探討
Acute ischemic stroke and peripheral arterial occlusion disease related factors
作者: 邱美春
Chiu, Mei-Chun
關鍵字: Acute ischemic stroke
急性缺血性中風
peripheral arterial occlusion disease
Ankle Brachial Index
周邊動脈阻塞疾病
踝肱指數
出版社: 生命科學院碩士在職專班
引用: 參考文獻 1.行政院衛生署(2010)•九十八年台灣十大死因統計•2010年9月30日,取自http://www.doh.gov.tw/ 2.Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985; 71:510-515. 3.Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation. 1985; 91:1472-1479. 4.Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004; 110:738-743. 5.Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001; 286:1317-1324. 6.Ostchega Y, Paulose-Ram R, Dillon CF, Gu Q, Hughes JP. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999–2004. J Am Geriatr Soc. 2007; 55:583-589. 7.American Heart Association. Heart Disease and Stroke Statistic -2010 Update Dallas. 8.Murabito JM, Evans JC, Larson MG, Nieto K, Levy D, Wilson PWF. The anklebrachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. Arch Intern Med. 2003; 163:1939-1942. 9.Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study: the Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol. 1999;19:538-545. 10.Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992; 326:381-6. 11.Criqui MH, Fronek A, Klauber MR, Barrett-Connor E, Gabriel S. The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral aterialdisease: results from noninvasive testing in a defined population. Circulation. 1985; 71:516-522. 12. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for VascularNursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006; 47:1239-1312. 13.Bernstein EF, Fronek A. Current status of noninvasive tests in the diagnosis of peripheral arterial disease. Surg Clin North Am. 1982; 62: 473-487. 14.Norgren L, Hiatt W, Dormandy J, Nehler M, Harris K, Fowkes F. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007; 33:S1-S75. 15. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and Edinburgh Artery prevalence of asymptomatic and symptomatic peripheral arterial disease in the general Study: population. Int J Epidemiol. 1991; 20:384-392. 16.Steg PG, Bhatt DL, Wilson PW, D''Agostino R Sr, Ohman EM, Röther J et al. REACH Registry Investigators. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis. JAMA. 2007; 297:1197-1206. 17.Milani RV, Lavie CJ. The role of exercise training in peripheral arterial disease. Vasc Med. 2007; 12:351-358. 18. McDermott MM, Mehta S, Greenland P. Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease. Arch Intern Med. 1999; 159:387-392. 19. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc. 1985; 33:13-18. 20.Mcdermott MM, Criqui MH, Greenland P, Guralnik JM, Liu K, Pearce WH, et al. Leg strength in peripheral arterial disease: associations with disease severity and lower-extremity performance. J Vasc Surg. 2004; 39:523-530. 21.Jelnes R, Gaardsting O, Hougaard JK, Baekgaard N, Tonnesen KH, Schroeder T: Fate in intermittent claudication: outcome and risk factors. Br Med J (Clin ResEd ). 1986; 293:1137-1140. 22. Dormandy JA, Rutherford RB, for the TASC Working Group. TransAtlantic InterSociety Consensus (TASC). Management of peripheral arterial disease (PAD). J Vasc Surg. 2000; 31:S1-296. 23. Marston WA, Davies SW, Armstrong B, Farber MA, Mendes RC, Fulton JJ, et al. Natural history of limbs with arterial insufficiency and chronic ulceration treated without revascularization. J Vasc Surg. 2006; 44:108-114. 24. Armstrong DG, Lavery LA. Diabetic foot ulcers: prevention, diagnosis and classification. Am Fam Physician. 1998; 57:1325-1332. 25. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation.Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. 2002; 106:3143-3421. 26. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of Tells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 1986; 6:131-138. 27. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med.1999; 40:115-126. 28.Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science. 1973; 180:1332-1339. 29.Poredos P. Endothelial dysfunction in the pathogenesis of atherosclerosis. Clin Appl Thromb Hemost. 2001; 7:276-280. 30.Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med. 1999; 107:85-97. 31.Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol. 1998; 18:842-851. 32.Pradhan AD, Rifai N, Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation. 2002; 106:820-825. 33.Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989; 84:1086-1095. 34. Brown MS, Goldstein JL. Lipoprote in metabolism in the macrophage. Annu Rev Biochem. 1983; 52:223-261. 35. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol. 1996; 16:831-842. 36.S D Cushing, J A Berliner, A J Valente, M C Territo, M Navab, F Parhami, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A. 1990; 87:5134-5138. 37.Ishii H, Kizaki K, Horie S, Kazama M. Oxidized Low Density Lipoprotein Reduces Thrombomodulin Transcription in Cultured Human Endothelial Cells through Degradation of the Lipoprotein in Lysosomes. J Biol Chem. 1996; 271:8458-8465. 38.Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation. 1990; 82: II 38-46. 39. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994; 90:2126-2146. 40.Idem. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993; 362:801-809. 41.Libby P. Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization. Am J Cardiol. 2000; 86:3J-8J. 42.Collins TC, Petersen NJ, Suarez-Almazor M, Ashton CM. The prevalence of peripheral arterialdisease in a racially diverse population. Arch Intern Med. 2003; 163:1469 -1474. 43.Criqui MH, Vargas V, Denenberg JO, Ho E, Allison M, Langer RD, et al. Ethnicity and peripheral arterial disease: the San Diego Population Study. Circulation. 2005; 112: 2703-2707. 44.Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol.1991; 20:384-392. 45. Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J. 2002; 143:961-996. 46.Murabito JM, D''Agostino RB, Silbershatz H, Wilson WF.Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation.1997; 96:44-49. 47.Jonason T, Bergström R.Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand. 1987; 221:253-260. 48.Krupski WC. The peripheral vascular consequences of smoking. Ann Vasc Surg. 1991; 5:291-304. 49. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004; 141:421-431. 50.Costa LA, Canani LH, Lisbôa HR, Tres GS, Gross JL. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic compllications in Type 2 diabetes. Diabet Med. 2004; 21:252-255. 51.Ross Russell. Atherosclerosis- An inflammatory disease. N Engl J Med. 1993; 340:115-126. 52.Newman AB, Tyrrell KS, Kuller LH. Mortality over four years in SHEP participants with a low ankle-arm index. J Am Geriatr Soc. 1997; 45:1472-1478. 53.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA. 2001; 285:2486-2497. 54.Retterstol L., Eikvar L., Bohn M., Bakken A., Erikssen J, Berg K. C-reactive protein predicts death in patients with previous premature myocardial infarction- a 10 year follow-up study. Atherosclerosis. 2002; 160: 433-440. 55.Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation. 2003; 7: 391-397. 56.林世鐸、杜思德、謝芳傑 、許上人、林國川、許惠恆(2004)•高敏感度C-反應蛋白 (hsCRP) 在偵測及預防心血管疾病方面的臨床應用• J Intern Med Taiwan. 2004; 15: 43-48。 57.徐嘉吟、方信智(2006)•心血管疾病指標-高敏感度C-反應蛋白 (hsCRP)• 基層醫學21:63-67。 58.Asfar S, Safar HA. Homocysteine levels and peripheral arterial occlusive disease a prospective cohort study and review of the literature. J Cardiovasc Surg (Torino). 2007; 48:601-605. 59.CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996; 348:1329-1339. 60. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. REACH Registry Investigators. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis. JAMA. 2006; 295:180-189. 61. Greenland P, Abrams J, Aurigemma GP, Bond MG, Clark LT, Criqui MH, et al. Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation. 2000; 101:E16-22. 62.Lange S, Trampisch HJ, Pittrow D, Darius H, Mahn M, Allenberg J, et al. get ABI Study Group. Profound influence of different methods for determination of the ankle brachial index on the prevalence estimate of peripheral arterial disease. BMC Public Health. 2007; 7:147. 63.McDermott MM, Criqui MH, Liu K, Guralnik JM, Greenland P, Martin GJ, et al. Lower ankle brachial index by averaging the dorsalis pedal and posterior tibial artery pressure is most closely associated with leg function in peripheral arterial disease. J Vasc Surg. 2003; 32:1164-1171. 64.Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation. 2003; 107:753-756. 65.Criqui MH, Denenberg JO. The generalized nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronary artery disease. Vasc Med. 1998; 3: 241-245. 66. Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensiveblood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation. 2003; 107:753-756. 67.Hiatt WR. Medical Treatment of peripheral arterial disease and claudication. N Engl J Med. 2001; 344:1608-1621. 68.Krupski WC. The peripheral vascular consequences of smoking. Ann Vasc Surg. 1991; 5:291-304. 69.Girolami B, Bernardi E, Prins MH, Ten Cate JW, Hettiarachchi R, Prandoni P, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: A meta-analysis. Arch Intern Med. 1999; 159:337-345. 70.Smith I, Franks PJ, Greenhalgh RM, Poulter NR, Powell JT. The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia. Eur J Vasc Endovasc Surg. 1996; 11:402-408. 71.Jonason T, Ringqvist I. Changes in peripheral blood pressures after five years of follow-up in non-operated patients with intermittent claudication. Acta Med Scand. 1986; 220:127-132. 72.Reunanen A, Takkunen H, Aromaa A. Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand. 1982; 211; 249-225. 73.Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication: effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand. 1987; 221:253-260. 74. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Arch Intern Med. 2005; 142:233-239. 75.Tonstad S, Farsang C, Klaene G, Lewis K, Manolis A, Perruchoud AP, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J. 2003; 24:946-955. 76.Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999; 340:685-691. 77.Willigendael EM, Teijink JA, Bartelink ML, Peters RJ, Büller HR, Prins MH. Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg. 2005; 42:67-74. 78.Pedersen TR, Kjekshus J, Pyörälä K, Olsson AG, Cook TJ, Musliner TA, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinan simvastatin survival study (4S). Am J Cardiol. 1998; 81:333-335. 79.An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program. JAMA. 1999; 282:2051-2057. 80.Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Cholesterol Treatment Trialists'' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366:1267-1278. 81.Murabito JM, D''Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication: a risk profile from the Framingham heart study. Circulation. 1997; 96:44-49. 82.Heart Protection Study Collaborative Group. The Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360:7-22. 83.Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999; 341:410-418. 84.Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA. 2003; 289:2560-2572. 85.Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D''Agostino RB, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002; 287:1003-1010. 86.Lewington S, Clarke R, Qizilbash N, Peto R, Collins R.Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360:1903-1913. 87.Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. 2000; 35:539-543. 88.Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. Arch Intern Med. 1991; 151:1769-1776. 89.Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study investigators. N Engl J Med. 2000; 342:145-153. 90.American Diabetes Association: Standards of medical care in diabetes-2006. Diabetes Care. 2006; 29:S4-42. 91.Armstrong DG, Lavery LA. Diabetic foot ulcers: prevention, diagnosis and classification. Am Family Physician. 1998; 57:1325-1332. 92. American Diabetes Association: Peripheral arterial disease in people with diabetes. Diabetes Care. 2003; 26:3333-3341. 93. Antithrombotic Trialists'' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. British Medical Journal. 2002; 324:71-86. 94.陳惠明、林耀東、陳惠文•抗小板藥物和Cilostazol在周邊動脈阻塞疾病病的應用•台灣醫界2009;52:12-14。 95.Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, Bortey EB, et al. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial. Arch Intern Med. 1999; 159:2041-2050. 96.Dawson DL, Cutler BS, Meissner MH, Strandness DE, Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998; 98:678-686. 97.Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998; 27: 267-274. 98.Strandness DE Jr, Dalman RL, Panian S, Rendell MS, Comp PC, Zhang P, et al. Effect of cilostazol in patients with intermittent claudication: a randomized, doubleblind, placebo-controlled study. Vasc Endovascular Surg. 2002; 36:83-91. 99.Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ. 1996; 155: 1053-1059. 100.Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol. 2003; 42:1493-1531. 101.Stewart K, Hiatt W, Regensteiner J, Hirsch A. Exercise training for claudication. N Engl J Med. 2002; 347:1941-1951. 102.Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA. 1995; 27:4975-4980. 103.Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2000; CD000990. 104. Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev. 2006; CD005263. 105.Whittemore AD, Donaldson MC, Polak JF, Mannick JA. Limitations of balloon angioplasty for vein graft stenosis. J Vasc Surg. 1991; 14:340-345. 106.Brumberg RS, Back MR, Armstrong PA, Cuthbertson D, Shames ML, Johnson BL, et al. The relative importance of graft surveillance and warfarin therapy in infrainguinal prosthetic bypass failure. J Vasc Surg. 2007; 46:1160-1166. 107.Goh RH, Sniderman KW, Kalman PG. Long-term follow-up of management of failing in situ saphenous vein bypass grafts using endovascular intervention techniques. J Vasc Interv Radiol. 2000; 11:705-712. 108.Olsen PS, Gustafsen J, Rasmussen L, Lorentzen JE. Long-term results after arterial surgery for arteriosclerosis of the lower limbs in young adults. Eur J Vasc Surg. 1988; 2:15-18. 109.Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989; 20: 864-870. 110.Goldstein LB, Bertels C, Davis JN. Interrater reliability of the NIH stroke scale. Arch Neurol. 1989; 46:660-662. 111.Spilker J, Kongable G, Barch C, Braimah J, Brattina P, Daley S, et al. Using the NIH Stroke Scale to assess stroke patients. The NINDS rt-PA Stroke Study Group. J Neurosci Nurs. 1997; 29:384-392. 112.Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, et al. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke. 1994; 25:2220-2226. 113.Adams HP Jr, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology. 1999; 53: 126-131. 114.Schlegel D, Kolb SJ, Luciano JM, Tovar JM, Cucchiara BL, Liebeskind DS, et al. Utility of the NIH stroke scale as a pedictor of hospital disposition. Stroke. 2003; 34:134-137. 115.鄭貴月、邱素真、孫漬官、葉淑惠、張谷州、陳廷耀、林祖功(2008)•台灣地區神經科醫護人員對美國國家衛生研究院腦中風評估量表之臨床應用•實證護理2:189-200 116.Mahoney F. Barthel D. Functional evaluation: the Barthel Index. Md Med J. 1965; 14:61- 65. 117.McDowell I, Newell C (1996). Measuring health: A guide to rating scales and questionnaires. (2nd ed.) New York: Oxford Univeraity Press. 51:104-106. 118.Sulter G, Steen C, De Keyser J. Use of the Barthel Index and Modified Rankin Scale in Acute Stroke Trials Stroke. Stroke. 1999; 30:1538-1541. 119.吳麗芬(2000).復健護理.於吳麗芬、邱愛富、高淑芬、徐畢卿、陳玉敏、陳靜敏等合著,當代老年護理學(443-458).台北:華杏 120.陳佳鳳、卓妙如、溫千慧、楊仲棋(2007)•運用巴氏量表於出血性腦中風患者復健治療三個月成效追蹤•台灣家醫誌 17:250-259。 121.van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke.1988; 19: 604-607. 122.Duncan PW, Jorgensen HS, Wade DT. Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice. Stroke. 2000; 31:1429 -1438. 123.Hacke W, Kaste M, Fiechi C, von Kummer R, Davalos A, Meier D, et al. for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998; 352:1245-1251. 124.Tilley BC, Marler J, Geller NL, Lu M, Legler J, Brott T, et al. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA stroke trial. Stroke.1996; 27: 2136- 2142. 125.de Haan R, Limburg M, Bossuyt P, van der Meulen J, Aaronson N. The clinical meaning of Rankin ‘handicap’ grades after stroke. Stroke. 1995; 26:2027-2030. 126.Diener HC: Modified-release dipyridamole combined with aspirin for secondary stroke prevention. Aging Health. 2005; 1:19-26. 127.Diener HC, Ringleb PA, Savi P: Clopidogrel for the secondary prevention of stroke. Expert Opin Pharmacothe. 2005; 6:755-764. 128.Weimar C, Diener HC, Alberts MJ, Steg PG, Bhatt DL, Wilson PW, et al. Reduction of Atherothrombosis for Continued Health Registry Investigators: The Essen Stroke Risk Score predicts recurrent cardiovascular events: a validation within the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Stroke. 2009; 40:350-354. 129.Weimar C, Goertler M, Rother J, Ringelstein EB, Darius H, Nabavi DG, et al. SCALA Study Group: Systemic risk score evaluation in ischemic stroke patients (SCALA): a prospective cross-sectional study in 85 German stroke units. J Neurol. 2007; 254:1562-1568. 130.Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care. 2002; 25: 894-899. 131.S. Tavintharan, Ning Cheung, Su Chi Lim, Wanting Tay, Anoop Shankar, E. Shyong Tai and Tien Y. Wong(2009)Prevalence and risk factors for peripheral artery disease in an Asian population with diabetes mellitus. Diab Vasc Dis Res. 2009; 6; 80-86. 132.Izzo JL Jr, Levy D, Black HR. Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-1024. 133.Tsivgoulis G, Alexandrov AV, Wadley VG, Unverzagt FW, Go RC, Moy CS, et al. Association of higher diastolic blood pressure levels with cognitive impairment. Neurology. 2009; 73:589-595. 134.Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists'' Collaboration. Lancet. 2000; 356:1955-1964. 135.Tseng CH. Prevalence and risk factors of peripheral arterial obstructive disease in Taiwanese type 2 diabetic patients. Angiology. 2003; 54:331-338. 136.Rhee SY, Guan H, Liu ZM, Cheng SW, Waspadji S, Palmes P, et al. PAD-SEARCH Study Group.Multi-country study on the prevalence and clinical features of peripheral arterial disease in Asian type 2 diabetes patients at high risk of atherosclerosis. Diabetes Res Clin Pract. 2007; 76:82-92. 137.Widlansky ME, Sesso HD, Rexrode KM, Manson JE, Gaziano JM. Body Mass Index and Total and Cardiovascular Mortality in Men With a History of Cardiovascular Disease. Arch Intern Med. 2004; 164:2326-2332. 138.Hu G, Tuomilehto J, Silventoinen K, Sarti C, Männistö S, Jousilahti P. Body mass index, waist circumference, and waist-hip ratio on the risk of total and typespecific stroke. Arch Intern Med. 2007; 167:1420-1427. 139.Barba R, Bisbe J, Pedrajas JN, Toril J, Monte R, Muñoz-Torrero JF, et al. FRENA Investigators. Body mass index and outcome in patients with coronary, cerebrovascular, or peripheral artery disease: findings from the FRENA registry Eur J Cardiovasc Prev Rehabil. 2009; 16:457-463. 140.Wild SH, Byrne CD, Smith FB, Lee AJ, Fowkes FG. Low ankle-brachial pressure index predicts increased risk of cardiovascular disease independent of the metabolic syndrome and conventional cardiovascular risk factors in the Edinburgh Artery Study. Diabetes Care. 2006; 29:637-642. 141.Huang KL, Lee TH, Ryu SJ, Chang YJ. Prediction of worse outcome by systemic atherosclerosis following acute ischemic stroke. Acta Neurologica Taiwanica.2008; 17:88-93. 142.opakian R, Nanz S, Rohrbacher B, Koppensteiner R, Aichner FT; OECROSS Study Group. High prevalence of peripheral arterial disease in patients with acute ischaemic stroke. Cerebrovasc Dis. 2010; 29:248-254. 143.Cheng SW, Wu LL, Lau H, Ting AC, Wong J. Prevalence of significant carotid stenosis in Chinese patients with peripheral and coronary artery disease. Aust N Z J Surg. 1999; 69:44-47.
摘要: 本研究利用踝肱指數(Ankle Brachial Index¸ABI) 探討急性缺血性中風患者與周邊動脈阻塞疾病(peripheral arterial occlusion disease;PAOD )相關因素。急性缺血性中風住院病人為收案對象,對象限制須為神經缺損症狀產生10天內住院,需經電腦斷層攝影排除出血性中風,總共收案166人,踝肱指數正常(0.91≦ABI≦1.3)128人,踝肱指數不正常(ABI≦0.9)有38人。所有收案病人平均年齡為68.4±9.7歲,男性佔61.4%(n=102),大於等於65歲以上患者佔66.3%。研究危險因子,有中風病史、高血壓、糖尿病,心臟疾病、抽菸者等。綜合卡方檢定、 Student t檢定、費雪精確檢定(Fisher''s Exact test)與多變項邏輯式分析,結果顯示影響缺血性腦中風合併罹患周邊動脈阻塞疾病最大之變項依序為年齡(勝算比:1.1;95%信賴區間1.0-1.2),空腹血糖(勝算比:1.0;95%信賴區間1.0-1.0),由此知道年齡和空腹血糖是罹患周邊動脈阻塞疾病非常重要因素。埃森中風風險指數(Essen Stroke Risk Score)大於2者其屬再中風高風險,我們病人中,84.2%患者罹患周邊動脈阻塞疾病合併埃森中風風險指數>2 。由以上結果知道缺血性中風患者合併周邊動脈阻塞疾病,易再次發生中風望藉由本次研究,提供另一個預測預後的選項。
We investigate the relationship between peripheral arterial occlusive disease (PAOD) and acute ischemic stroke by ankle brachial index (ABI).The inclusive criteria were the in-patents who suffered from an acuteischemic stroke, and were admitted within 10 days.Ischemic stroke wereconfirmed by brain computed tomography (CT). Among 166 patientscollected, 38 patients had abnormal ABI below 0.9, and the remaining patients were within normal range (0.91 to 1.3). The average age was68.4±9.7 years old, 61.4% were male(n=102)and those who were older than 65 years old was 66.3%. We studied risk factors such as age, previous stroke, hypertension, blood sugar, heart diseases, and smoking.We use Chi-square test, Student t test﹐Fisher''s Exact test and logistic regression. The resultsindicate that the most influential factors are age(Odds Ratio: 1.1; 95%CI) and fasting blood glucose(Odds Ratio: 1.0 ;95%CI). Also, we analyzed these patients using the Essenstroke risk score. The rate of recurrent stroke was highif the score was higher than 2. The data show that the percentage of patients with-in stroke-associated PAOD and high Essen Stroke Risk score was 84.2%. According to these data, patients who suffered from ischemic stroke associated with PAOD are more susceptible to recurrence of stroke.
URI: http://hdl.handle.net/11455/23524
其他識別: U0005-2101201112014700
文章連結: http://www.airitilibrary.com/Publication/alDetailedMesh1?DocID=U0005-2101201112014700
Appears in Collections:生命科學系所

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.